Wilczynski, M.; Kielbik, M.; Senderowska, D.; Krawczyk, T.; Szymanska, B.; Klink, M.; Bieńkiewicz, J.; Romanowicz, H.; Frühauf, F.; Malinowski, A.
MiRNA-103/107 in Primary High-Grade Serous Ovarian Cancer and Its Clinical Significance. Cancers 2020, 12, 2680.
https://doi.org/10.3390/cancers12092680
AMA Style
Wilczynski M, Kielbik M, Senderowska D, Krawczyk T, Szymanska B, Klink M, Bieńkiewicz J, Romanowicz H, Frühauf F, Malinowski A.
MiRNA-103/107 in Primary High-Grade Serous Ovarian Cancer and Its Clinical Significance. Cancers. 2020; 12(9):2680.
https://doi.org/10.3390/cancers12092680
Chicago/Turabian Style
Wilczynski, Milosz, Michal Kielbik, Daria Senderowska, Tomasz Krawczyk, Bozena Szymanska, Magdalena Klink, Jan Bieńkiewicz, Hanna Romanowicz, Filip Frühauf, and Andrzej Malinowski.
2020. "MiRNA-103/107 in Primary High-Grade Serous Ovarian Cancer and Its Clinical Significance" Cancers 12, no. 9: 2680.
https://doi.org/10.3390/cancers12092680
APA Style
Wilczynski, M., Kielbik, M., Senderowska, D., Krawczyk, T., Szymanska, B., Klink, M., Bieńkiewicz, J., Romanowicz, H., Frühauf, F., & Malinowski, A.
(2020). MiRNA-103/107 in Primary High-Grade Serous Ovarian Cancer and Its Clinical Significance. Cancers, 12(9), 2680.
https://doi.org/10.3390/cancers12092680